Vaccination First Boosts Long-Term COVID-19 Immunity, Study Finds

The order in which a person is first exposed to SARS-CoV-2 – through vaccination or infection – significantly influences long-term immune response, particularly against variants like Omicron. This finding emerges from a new scientific study published in Nature Communications, conducted by researchers at the Barcelona Institute for Global Health (ISGlobal), in collaboration with the Institut Català de la Salut (ICS) and the Institut d’Investigació en Atenció Primària Jordi Gol (IDIAP JG).

Understanding Hybrid Immunity

Since the start of the pandemic, most individuals have developed what is known as hybrid immunity – a combination of vaccination and natural infection. Previous research has demonstrated that this type of immunity offers broader protection than either exposure alone. However, a key question remained: does the sequence of these exposures – vaccination first or infection first – impact the quality and duration of immune protection?

The study analyzed data from the CovidCatCentral cohort, comprised of healthcare professionals from Catalonia Central, a group with high exposure risk throughout the pandemic. Researchers followed 357 participants between 2020 and 2023, collecting periodic blood samples.

Of those participants, 160 were vaccinated before becoming infected, while 197 experienced infection before vaccination. Notably, 98% of the initial infections in the latter group occurred with the original Wuhan variant of the virus.

Did You Know? The study followed 357 healthcare professionals in Catalonia Central over a three-year period, collecting repeated blood samples to track immune responses.

Antibody Response: Vaccination First Offers an Advantage

The results indicate that individuals whose initial exposure was vaccination developed higher levels of IgG and IgA antibodies against multiple Omicron lineages compared to those who were first infected. This difference was particularly pronounced in antibodies targeting the receptor binding domain of the Spike protein – a critical region for viral entry into cells.

Researchers emphasize that this immunological advantage isn’t permanent, diminishing as individuals accumulate more exposures or receive additional vaccine doses. However, the data suggests that vaccination as the first encounter with the antigen shapes a more effective antibody response against variants distant from the original virus.

Cellular Response: Cautious Interpretation Needed

The study also observed a somewhat more intense T cell response in individuals who were initially infected, potentially due to exposure to a wider range of viral antigens or higher viral loads during infection. However, the authors caution that these findings should be interpreted carefully, as the number of participants specifically evaluated for cellular immunity was limited. The study does not allow for definitive conclusions about the superiority of one pathway over the other in this specific aspect of the immune response.

Expert Insight: The observed differences in immune responses highlight the complex interplay between vaccination and natural infection in shaping long-term protection against evolving viruses. Understanding these nuances is crucial for optimizing vaccination strategies.

Clinical Protection Over Time

The observed immunological differences translated into variations in clinical protection against new infections. During the early phases of the pandemic, when variants closer to the original strain circulated, those initially infected demonstrated greater initial protection. However, with the emergence of Omicron, the situation reversed: individuals vaccinated first exhibited increased protection against subsequent infections, even within a context of hybrid immunity.

The authors state that these findings reinforce the idea that early vaccination not only provides short-term protection but also positively influences the quality of the long-term immune response against new variants.

Researchers stress that the study does not diminish the value of hybrid immunity, but rather helps to better understand how We see built and how it can be optimized. The results support the role of vaccination campaigns as a key tool for preparing the immune system against viral evolution.

This work is part of the European END-VOC project, aimed at improving the response to COVID-19 and future pandemics, and provides relevant information for designing vaccination strategies adapted to a scenario where the virus continues to evolve. More information about the study is available here.

Frequently Asked Questions

What is hybrid immunity?

Hybrid immunity is a combination of protection from vaccination and natural infection.

Did the study find a clear “best” order of exposure?

The study suggests that vaccination first leads to a more effective antibody response against variants like Omicron, while initial infection may lead to a slightly more intense T cell response, though further research is needed on that aspect.

Does this study change the importance of getting vaccinated?

No, the researchers insist the study does not question the value of hybrid immunity, but rather helps to understand how it is built and how it can be optimized. The results support the role of vaccination campaigns.

As the virus continues to evolve, how might future vaccination strategies be adapted based on these findings?